Archives
The business of Pharmacogenomics: Assessing biotechnology's promise in quantitative terms
Enal S Razvi
Director, Business Development, LJL BioSystems Inc
Abstract
This article presents an overview of the valuation strategy constructed by the author with assistance from former colleagues from Biotechnology Industry Research of Frost & Sullivan for determining the inherent value in a given genomics-based therapeutic category. The methodology focuses upon future market opportunities (in prospective sales of pharmaceuticals) and their relevance in terms of current dollars invested in constructing these paradigms.
"Accurate valuations will help both parties make intelligent investments, whether it be through purchasing the technology, licensing or collaboration."
eContent Home